Significant Efficacy: In the 36-week REZOLVE-AA trial, the 24 µg/kg dose group achieved an average SALT score reduction of 28.2%, compared to only 11.2% in the placebo group, indicating substantial clinical efficacy and potential for hair loss treatment.
Statistical Significance: Excluding four patients who did not meet major eligibility criteria, the SALT score reductions were 29.6% for the 24 µg/kg group and 30.4% for the 18 µg/kg group, both achieving statistical significance (p<0.05), laying a solid foundation for the planned Phase 3 trials.
Good Safety Profile: Rezpegaldesleukin demonstrated a safety profile consistent with prior studies, with nearly all treatment-emergent adverse events being mild to moderate and self-resolving, indicating good tolerability for long-term treatment.
Future Development Plans: Nektar aims to advance Rezpegaldesleukin into Phase 3 trials in 2026, leveraging its Fast Track designation to expedite the availability of this potential treatment to patients in urgent need.
NKTR
$48.68+Infinity%1D
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 93.86 USD with a low forecast of 30.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 93.86 USD with a low forecast of 30.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 53.300
Low
30.00
Averages
93.86
High
120.00
Current: 53.300
Low
30.00
Averages
93.86
High
120.00
Citi
NULL
to
Buy
initiated
$102
2025-11-26
Reason
Citi
Price Target
$102
2025-11-26
initiated
NULL
to
Buy
Reason
Citi initiated coverage of Nektar with a Buy rating and $102 price target. Citi also opened a "positive 90-day catalyst watch" on Nektar ahead of the Phase 2b alopecia areata data expected in December. The firm believes data for rezpegaldesleukin in atopic dermatitis "look competitive" in crowded field. It sees an "asymmetrical upside" opportunity for the shares into the December readout.
Jefferies
Buy
upgrade
$99 -> $121
2025-11-26
Reason
Jefferies
Price Target
$99 -> $121
2025-11-26
upgrade
Buy
Reason
Jefferies raised the firm's price target on Nektar to $121 from $99 and keeps a Buy rating on the shares. With "relatively low expectations" going into Nektar's Rezpeg reporting Phase 2b topline data in Alopecia Areata in December, the firm sees "significant upside potential and limited downside" given Rezpeg's novel mechanism of action, clean safety profile and durability potential, the analyst tells investors. The firm is adding AA to its model with 20% odds of success and about $300M in estimated peak sales.
Jefferies
Roger Song
Buy
maintain
$69 -> $99
2025-09-18
Reason
Jefferies
Roger Song
Price Target
$69 -> $99
2025-09-18
maintain
Buy
Reason
Jefferies analyst Roger Song raised the firm's price target on Nektar to $99 from $69 and keeps a Buy rating on the shares after the company announced data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin. The positive patient-reported outcome assessments add further support for rezpegaldesleukin's benefit in atopic dermatitis and complimented the efficacy data reported in June, the analyst tells investors in a research note. Jefferies upped the drug's probability of success to 55% from 45%.
Oppenheimer
Oppenheimer
Outperform
upgrade
$90 -> $98
2025-08-08
Reason
Oppenheimer
Oppenheimer
Price Target
$90 -> $98
2025-08-08
upgrade
Outperform
Reason
Oppenheimer raised the firm's price target on Nektar to $98 from $90 and keeps an Outperform rating on the shares following quarterly results. The firm notes Q2 marks an important milestone for Nektar, as the company reported positive topline results from the Phase 2b REZOLVE-AD study of rezpeg in atopic dermatitis. Oppenheimer anticipates additional updates in the coming months, including data presentation in the second half of the year at a medical conference; alopecia areata topline results in December; and maintenance data from REZOLVE-AD in Q1 2026.
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
